- Adjuvants in allergen Immunotherapy | EAACI.org

Ongoing Task Forces

- Adjuvants in allergen Immunotherapy

aiait

The AiAIT task force aims to critically discuss the role of adjuvants and carriers in allergen immunotherapy, both in the context of tolerance induction or novel vaccination concepts. The Task force Adjuvants in Allergy was approved in November 2016.

Aims:
·         To evaluate the state of the art in established adjuvants
·         To determine the immune effects associated with adjuvants
·         To evaluate their risks and outweigh with the benefits
·         To critically assess novel adjuvants and formulations potentially suitable in AIT

Thomas Kundig and Erika Jensen Jarolim

Picture: TF secretary Erika Jensen-Jarolim with TF chair Thomas Kündig
 
Please find the full list of task force members here.
Last updated 07 June 2018
Privacy Policy - disclaimer

EAACI recently updated its privacy policy and would like to highlight some key bits of information with you.

  • EAACI does not distribute, share or sell your information;
  • For technical and administrative purposes some information that can be used to identify you may be forwarded to third parties. For example, to process your registration for the EAACI Annual Congress and other EAACI events;
  • The Academy may also send you e-mail messages with news from the society. If you would like to no longer receive them, you can unsubscribe at any time by using the unsubscribe link in any of our communications;
  • You may also update your preferences or your profile information at any time by contacting us.

To continue please confirm that you agree with our updated privacy policy.

Thank you!

You have successfully agreed the new privacy policy – disclaimer.

Thank you!

You disagreed with the new privacy policy – disclaimer and your feedback will be reviewed as soon as possible.

Agree & Continue
Disagree
Send feedback
Cancel